Soleno Therapeutics' lead asset, DCCR, targets Prader-Willi Syndrome (PWS) but faces a small market and IP challenges, with potential in other hyperphagic conditions. Despite positive trial data ...

But for a small number of children, the infection triggers strange behavior changes known as PANDAS syndrome. PANDAS stands for Pediatric Autoimmune Neuropsychiatric Disorders Associated with ...

Acadia Pharmaceuticals ACAD announced that it has signed an exclusive worldwide license agreement with Saniona, a Denmark-based clinical-stage biopharmaceutical company, to develop and ...

Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient ...

(SLNO) Tuesday announced that the FDA has extended the review period for the New Drug Application for DCCR tablets targeted at patients with Prader-Willi syndrome. DCCR is a proprietary extended ...

The treatment aims at hyperphagia in patients four years of age and above with Prader-Willi syndrome. The FDA's decision that responds to recent information requests significantly changed the NDA ...